Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 1, January-February, p. 55–62

doi: 10.17219/acem/29264

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Cytotoxic Activity of Valproic Acid on Primary Chronic Lymphocytic Leukemia Cells

Marta Karp1,B,C,D,F, Kamila Kosior2,B,C,D, Agnieszka Karczmarczyk1,D,E,F, Małgorzata Zając1,D,E,F, Joanna Zaleska1,D,E,F, Waldemar Tomczak2,D,E,F, Sylwia Chocholska2,D,E,F, Marek Hus2,D,E,F, Anna Dmoszyńska2,D,E,F, Krzysztof Giannopoulos1,2,A,B,C,D,E,F

1 Department of Experimental Hematooncology, Medical University of Lublin, Poland

2 Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland


Background. Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in western civilization. The accumulation of CD5+CD19+ B lymphocytes in peripheral blood is due to a defect in the apoptotic pathway rather than excessive proliferation in the bone marrow and lymph nodes. Despite a number of treatments, CLL remains an incurable disease. Valproic acid (VPA) activity, as a histone deacetylase inhibitor, could restore the epigenetic changes underlying the pathogenesis of CLL and thus induce cell death.
Objectives. In the present study we hypothesized that VPA could induce CLL primary cells death through activation of apoptosis.
Material and Methods. Peripheral blood samples were obtained from 53 CLL patients. Peripheral blood mononuclear cells were isolated through density gradient centrifugation and were the subject of a 24-hour cell culture with 10 mM of VPA. The cytotoxic effect of VPA was evaluated with an XTT test and thereafter confirmed using Annexin V-FITC/PI staining and flow cytometry techniques.
Results. In this study, a median VPA cytotoxicity of 13.88% with a range of 0-54.65% was observed. Annexin V/PI staining confirmed that the demonstrated cytotoxicity was caused by increased apoptosis in the VPA treated cells as compared to control cells. Statistical analysis showed that VPA’s effect on CLL cells depends on lactate dehydrogenase serum levels, but is independent of all other prognostic markers.
Conclusion. The results of the present experiments found that VPA at a clinically applicable concentration significantly induces apoptosis independently of the disease stage and might be a valuable therapeutic agent for all CLL patients.

Key words

apoptosis, CLL, chronic lymphocytic leukemia, VPA, valproic acid.

References (23)

  1. Ghia P, Ferreri AJ, Caligaris-Cappio F: Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 2007, 64, 234–246.
  2. Giannopoulos K: Biologia i rokowanie w przewlekłej białaczce limfocytowej. Acta Hematol Pol 2010, 41, 433–440.
  3. Robak T: Czynniki prognostyczne w przewlekłej białaczce limfatycznej. Acta Hematol Pol 2003, 34, 395–405.
  4. Abbot BL: Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 2006, 11, 21–30.
  5. Zenz T, Mertens D, Dohner H, Stilgenbauer S: Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011, 25, 131–137.
  6. Robak T, Robak P: BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int Rev Immunol 2013, 32, 358–376.
  7. Kharfan-Dabaja MA, Wierda WG, Cooper LJN: Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 2014, 28, 507–517.
  8. Giannopoulos K, Mertens D, Stilgenbauer S: Targeting chronic lymphocytic leukemia with thalidomide and lenalidomide. Expert Opin Pharmacother 2011, 12, 2857–2864.
  9. Chen CI: Lenalidomide alone and in combination for chronic lymphocytic leukemia. Curr Hematol Malig Rep 2013, 8, 7–13.
  10. Skórka K, Bhattacharya N, Własiuk P, Kowal M, Mertens D, Dmoszyńska A, Giannopoulos K: Thalidomide regulation of NF-kB proteins limits Tregs activity in chronic lymphocytic leukemia. Adv Clin Exp Med 2014, 23, 25–32.
  11. Giannopoulos K, Dmoszyńska A, Kowal M, Wąsik-Szczepanek E, Bojarska-Junak A, Roliński J, Dohner H, Stilgenbauer S, Bullinger L: Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 2009, 23, 1771–1778.
  12. Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D: Valproic acid induces apoptosis in chronic lymphcytic leukemia cells trough activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 2007, 35, 1527–1537.
  13. Bokelmann I, Mahlknecht U: Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between proand antiapoptotic proteins. Mol Med 2008, 14, 20–27.
  14. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 24, 6969–6978.
  15. Duenas-Gonzales A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA: Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008, 34, 206–222.
  16. Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sexer O, Heider U: The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suspension and apoptosis in multiple myeloma. Haematologica 2006, 91, 248–251.
  17. Kawagoe R, Kawagoe H, Sano K: Valproic acid induces apoptosis in human leukemia cells by stimulationg both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 2002, 26, 495–502.
  18. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O, Marie JP: Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004, 18, 1246–1251.
  19. Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, Willis F, Burny A, Lagneaux L, Bron D, Chatelain B, Chatelain C, Willems L: Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2008, 144, 41–52.
  20. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DBJ, Dyer MJS, Cohen GM: Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005, 12, 773–782.
  21. Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, Lagneaux L: Antileukemiac activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 2009, 23, 2281–2289.
  22. Yoon JY, Ishdorj G, Graham BA, Johnston JB, Gibson SB: Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation of B-cell-lymphoid neoplastic cells. Apoptosis 2014, 19, 191–200.
  23. Yoon JY, Szwajcer D, Ishdorj G, Benjaminson P, Xiao W, Johnston JB, Gibson SB: Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B. Blood Cancer J 2013, 3, 153.